SCHEMBL25546014

SCHEMBL25546014

COCCOc1cc(-c2nc(Cl)sc2CC(C)(C)C)ccc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
HPGD P15428 2/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TRPV1 Q8NER1 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.35
POLB P06746 2/20 0.35
MAPT P10636 2/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
CYP2C9 P11712 1/20 0.35
ALOX12 P18054 1/20 0.35
MAPK1 P28482 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HTR2C P28335 2/20 0.34
S1PR4 O95977 1/20 0.34
HTR2B P41595 1/20 0.34
PIK3CD O00329 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25180286 0.87 GRM2 (0.41) ALDH1A1HPGDSMN1; SMN2TRPV1L3MBTL1
SCHEMBL25546067 0.87 RIPK2 (0.41) ALDH1A1MAPTGRM2LMNADYRK1A
SCHEMBL25545980 0.87 ALDH1A1 (0.36) ALDH1A1HPGDHTTSMN1; SMN2MAPK1
SCHEMBL25556509 0.86 AR (0.40) ALDH1A1HPGDHTTSMN1; SMN2
SCHEMBL25546010 0.84 XDH (0.35) ALDH1A1FBP1GRM2MGAMGAA
SCHEMBL25183737 0.84 FBP1 (0.45) ALDH1A1HPGDHTTSMN1; SMN2TRPV1
SCHEMBL25556325 0.83 LMNA (0.32) MAPTFBP1GRM2LMNADYRK1A
SCHEMBL25546020 0.82 TRPV1 (0.43) ALDH1A1HPGDHTTSMN1; SMN2TRPV1
SCHEMBL25546008 0.82 IGF1R (0.39) SMN1; SMN2MAPTMEN1CYP2C9CYP2C19
SCHEMBL25545936 0.78 PAX8 (0.39) ALDH1A1L3MBTL1MAPTMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 ALDH1A1 4776/4885HPGD 4535/4885HTT 1458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.